MedTrace Logo

Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801

NCT01604746 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1146

Last updated 2015-10-09

No results posted yet for this study

Summary

The purpose of this study is to verify the long-term safety of a 2.5 µg, adjuvanted (aluminium hydroxide) dose of Ross River Virus (RRV) vaccine.

Conditions

  • Prophylaxis of Ross River Virus Infection

Interventions

BIOLOGICAL

Ross River Virus (RRV) Vaccine

Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.

Sponsors & Collaborators

  • Alachua Government Services, Inc.

    lead INDUSTRY

Principal Investigators

  • Gerald Aichinger, MD · Baxter Innovations GmbH

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01604746 on ClinicalTrials.gov